Topic:
Device Studies
Latest Headlines
Latest Headlines
Stentys self-apposing cardiac stent gets the job done at one year
France's Stentys is celebrating more positive clinical data stemming from the use of its self-apposing stent to treat acute heart attacks.
St. Jude, CardioKinetix tout impressive data at EuroPCR
The industry has descended on Paris to talk stents, valves and drug elution at EuroPCR, touting new technologies to an audience of the world's cardiovascular decisionmakers. Check out the highlights from Day Three >>
Boston Scientific's strong results fuel hope for renal denervation success
Boston Scientific made a splash when it spent $425 million on 2012 Fierce 15 winner Vessix Vascular last year, and now, with strong interim data for its newly acquired renal denervation system, the company has a shot to compete for market share in the soon-to-boom space.
Covidien ablation device wows in Barrett's esophagus reversal
Covidien is celebrating results from a trial showing one of its ablation therapy devices helped prevent an advance to esophageal cancer by eliminating a precancerous condition known as Barrett's esophagus.
Boston Scientific, Elixir make waves at EuroPCR 2013
A who's who of medical device outfits have taken to Paris this week for EuroPCR, flaunting their latest data and devices to a gathering of the continent's interventional cardiovascular specialists. Here's a look at the highlights from Day Two >>
Medtronic, J&J's Cordis headline EuroPCR 2013
EuroPCR kicked off in Paris on Tuesday, bringing devicemakers from around the globe together to unveil data and angle for attention from the continent's interventional cardiovascular specialists. Here's a look at some early highlights from the conference.
Medtronic wins CE mark for clot-removal tech
Medtronic snagged a CE mark for the Export Advance aspiration catheter, planning to launch the clot-removing device in Europe and other international markets.
Boston Scientific launches stent study for pancreatic cancer surgery
Boston Scientific enrolled its first patient in a study of its self-expanding WallFlex Biliary RX Stent to broaden the indication of the device for the purposes of draining bile before pancreatic cancer surgery.
St. Jude touts Durata's safety amid abrasion worries
St. Jude Medical's much-scrutinized defibrillator leads remained almost 100% safe from abrasion and mechanical failure after 5 years, according to an independent analysis, results the company hopes will quiet alarm from regulators and competitors.
Boston Scientific: Watchman beats warfarin in follow-up
Boston Scientific's Watchman is more effective in preventing stroke than standard-of-care warfarin, according to a study, giving the company some renewed hope for the device's FDA approval and eventual large market leadership.
